Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear infection and compensated cirrhosis research[1][2].
[1]. Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge•) step in the right direction. Liver Int. 2021 Jul;41(7):1441-1442.
[2]. Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28(6):852-858.
















